CoSara set to serve Indians

 

Co-Diagnostics, Inc.

Utah’s Co-Diagnostics, Inc. (Nasdaq: CODX) said its joint venture for manufacturing has obtained regulatory clearance for five tests to be manufactured and sold as in vitro diagnostics (IVDs) from their facility in Ranoli.

The joint venture CoSara Diagnostics Pvt Ltd has received the clearance, said the molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests.

The Saragene™ tests for Mycobacterium tuberculosis, malaria, hepatitis B, hepatitis C and human papillomavirus (HPV) meet the requirements of the Central Drug Standard Control Organization (CDSCO) Medical Device Rules (MDR) 2017, File no. 29/Misc./3/2017-DC (292), to be manufactured and sold as IVDs.

CDSCO approval was granted following the completion of the CoSara manufacturing facility and a comprehensive inspection of the location, presentation of the technology, quality system, procedures, product validation data and performance evaluation by an independent NABL & CAP accredited laboratory.

The licenses and regulatory clearance allow CoSara for the first time to manufacture and sell the tests for the detection of the respective pathogens and microorganisms, Co-Diagnostics said on 3 Dec 2019.

CoSara distributors have begun taking pre-orders for the five IVDs, and the Company expects sales to ramp quickly. The JV has the exclusive manufacturing rights in India for the complete menu of Co-Diagnostics infectious disease molecular diagnostics kits, designed by Co-Diagnostics using their patented CoPrimer™ technology platform.

Additional tests, which are expected to be submitted to the CDSCO for approval, consist of those for drug-resistant tuberculosis, HIV and more, including a multiplexed panel specifically for blood-bank screening.

Company CEO Dwight Egan remarked “India is soon to become the largest healthcare market on the planet and the best place for Co-Primer-powered products to be manufactured and distributed is from within the country itself.

“Being able to sell fully approved IVDs to this market represents the next stage in our growth as we establish Co-Diagnostics to be a leading innovator of high-quality, affordable diagnostics solutions. We are excited to be taking this next step in our growth with such a distinguished partner and are eager to see returns on the time and effort we have spent to get to this point,” said Egan.

The CoSara plant is one of the first facilities for manufacturing molecular diagnostics in India and has been designed to meet both current and future requirements for medical device manufacturing, which are expected to be implemented by the Indian government.

CoSara is a joint venture between the Company and Synbiotics Pvt Ltd, a group company of Asence Inc of the United States that specializes in supplying pharmaceutical products to international markets across 35 countries. Asence and Synbiotics are both subsidiaries of Ambalal Sarabhai Enterprises Ltd, a continuation of one of the oldest and most respected manufacturing institutions in India in operation today.

“We are honored to be the manufacturer of the first indigenous PCR-based diagnostic kits in India,” said Mohal Sarabhai, CEO of Synbiotics.

“Our team has worked tirelessly this year, ensuring the facility and procedures meet or exceed the requirements to fulfill our mandate of providing cutting-edge molecular diagnostics technology to India.

“The goals of the ‘make in India’ initiative aligns perfectly with those of CoSara, and we look forward to serving not only the Indian market but to receiving the CE markings and other necessary regulatory approvals that will allow CoSara Diagnostics to expand on a global scale,” said Sarabhai.

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology.

The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. fiinews.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here